Evaluation of the Incidence of Sensorineural Hearing Loss in Beta-Thalassemia major Patients under Regular Chelation Therapy with Desferrioxamine

Karimi, Mehran; A. Asadi‐Pooya, Ali; Khademi, Bijan; Asadipooya, Kamyar; Yarmohammadi, Hooman

doi:10.1159/000064748

Public

Evaluation of the Incidence of Sensorineural Hearing Loss in Beta-Thalassemia major Patients under Regular Chelation Therapy with Desferrioxamine

Published in Acta Haematologica • Jan 1, 2002

Authors:

Mehran Karimi

Ali A. Asadi‐Pooya

Bijan Khademi

Abstract

With the improved life expectancy of beta-thalassemia major patients, new clinical problems, such as hearing loss, must be evaluated. To determine the incidence of sensorineural hearing loss and its relationship to desferrioxamine (DFO), 128 patients receiving subcutaneous DFO in doses from 21 to 39...

View

Paywalled

Subject

Medicine

Ototoxicity

Sensorineural hearing loss

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Subject

Generate AI Take for this paper

Discussions